Literature DB >> 20233889

DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.

Kuan-Ting Kuo1, Tsui-Lien Mao, Xu Chen, Yuanjian Feng, Kentaro Nakayama, Yue Wang, Ruth Glas, M Joe Ma, Robert J Kurman, Ie-Ming Shih, Tian-Li Wang.   

Abstract

PURPOSE: Advanced ovarian clear cell carcinoma (CCC) is one of the most aggressive ovarian malignancies, in part because it tends to be resistant to platinum-based chemotherapy. At present, little is known about the molecular genetic alterations in CCCs except that there are frequent activating mutations in PIK3CA. The purpose of this study is to comprehensively define the genomic changes in CCC based on DNA copy number alterations. EXPERIMENTAL
DESIGN: We performed 250K high-density single nucleotide polymorphism array analysis in 12 affinity-purified CCCs and 10 CCC cell lines. Discrete regions of amplification and deletion were also analyzed in additional 21 affinity-purified CCCs using quantitative real-time PCR.
RESULTS: The level of chromosomal instability in CCC as defined by the extent of DNA copy number changes is similar to those previously reported in low-grade ovarian serous carcinoma but much less than those in high-grade serous carcinoma. The most remarkable region with DNA copy number gain is at chr20, which harbors a potential oncogene, ZNF217. This discrete amplicon is observed in 36% of CCCs but rarely detected in serous carcinomas regardless of grade. In addition, homozygous deletions are detected at the CDKN2A/2B and LZTS1 loci. Interestingly, the DNA copy number changes observed in fresh CCC tissues are rarely detected in the established CCC cell lines.
CONCLUSIONS: This study provides the first high resolution, genome-wide view of DNA copy number alterations in ovarian CCC. The findings provide a genomic landscape for future studies aimed at elucidating the pathogenesis and developing new target-based therapies for CCCs. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233889      PMCID: PMC2848895          DOI: 10.1158/1078-0432.CCR-09-2105

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Digital karyotyping.

Authors:  Tian-Li Wang; Christine Maierhofer; Michael R Speicher; Christoph Lengauer; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

2.  The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells.

Authors:  G H Nonet; M R Stampfer; K Chin; J W Gray; C C Collins; P Yaswen
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

3.  Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation.

Authors:  M Kiechle; A Jacobsen; U Schwarz-Boeger; J Hedderich; J Pfisterer; N Arnold
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

4.  Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas.

Authors:  Y Suehiro; M Sakamoto; K Umayahara; H Iwabuchi; H Sakamoto; N Tanaka; N Takeshima; K Yamauchi; K Hasumi; T Akiya; H Sakunaga; T Muroya; F Numa; H Kato; Y Tenjin; T Sugishita
Journal:  Oncology       Date:  2000-06       Impact factor: 2.935

5.  FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis.

Authors:  H Ishii; A Vecchione; Y Murakumo; G Baldassarre; S Numata; F Trapasso; H Alder; R Baffa; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.

Authors:  M M Tanner; S Grenman; A Koul; O Johannsson; P Meltzer; T Pejovic; A Borg; J J Isola
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.

Authors:  M Erzen; S Rakar; B Klancnik; K Syrjänen; B Klancar
Journal:  Gynecol Oncol       Date:  2001-10       Impact factor: 5.482

8.  A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes.

Authors:  Mohamed-Ali Hakimi; Yuanshu Dong; William S Lane; David W Speicher; Ramin Shiekhattar
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

9.  Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.

Authors:  Emanuela Veras; Tsui-Lien Mao; Ayse Ayhan; Stefanie Ueda; Hong Lai; Mutlu Hayran; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2009-06       Impact factor: 6.394

10.  Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation.

Authors:  J Dent; G D Hall; N Wilkinson; T J Perren; I Richmond; A F Markham; H Murphy; S M Bell
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  39 in total

1.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.

Authors:  Elisabetta Kuhn; Alan K Meeker; Kala Visvanathan; Amy L Gross; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

Review 2.  Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Authors:  Marieke A Vollebergh; Jos Jonkers; Sabine C Linn
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

3.  Ovarian Cancer Is an Imported Disease: Fact or Fiction?

Authors:  Elisabetta Kuhn; Robert J Kurman; Ie-Ming Shih
Journal:  Curr Obstet Gynecol Rep       Date:  2012-03

4.  Comparative analysis of somatic copy-number alterations across different human cancer types reveals two distinct classes of breakpoint hotspots.

Authors:  Yudong Li; Li Zhang; Robyn L Ball; Xinle Liang; Jianrong Li; Zhenguo Lin; Han Liang
Journal:  Hum Mol Genet       Date:  2012-08-16       Impact factor: 6.150

5.  Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.

Authors:  Daichi Maeda; Xu Chen; Bin Guan; Shunsuke Nakagawa; Tetsu Yano; Yuji Taketani; Masashi Fukayama; Tian-Li Wang; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2011-01       Impact factor: 2.762

6.  Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.

Authors:  Ie-Ming Shih; Li Chen; Chen C Wang; Jinghua Gu; Ben Davidson; Leslie Cope; Robert J Kurman; Jianhua Xuan; Tian-Li Wang
Journal:  Am J Obstet Gynecol       Date:  2010-10-20       Impact factor: 8.661

7.  Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

Authors:  Elisabetta Kuhn; Ren-Chin Wu; Bin Guan; Gang Wu; Jinghui Zhang; Yue Wang; Lei Song; Xiguo Yuan; Lei Wei; Richard B S Roden; Kuan-Tin Kuo; Kentaro Nakayama; Blaise Clarke; Patricia Shaw; Narciso Olvera; Robert J Kurman; Douglas A Levine; Tian-Li Wang; Ie-Ming Shih
Journal:  J Natl Cancer Inst       Date:  2012-08-23       Impact factor: 13.506

Review 8.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

9.  ARID1A mutation and genomic stability.

Authors:  Timothy Nacarelli; Bo Zhao; Xue Hao; Rugang Zhang
Journal:  Mol Cell Oncol       Date:  2020-02-23

10.  Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.

Authors:  Naoki Kawahara; Kenji Ogawa; Mika Nagayasu; Mai Kimura; Yoshikazu Sasaki; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.